Document is current
Any future updates will be listed below
-
Authors
Kwok, Darwin W.
Stevers, Nicholas O. https://orcid.org/0000-0003-1082-6423
Etxeberria, Iñaki https://orcid.org/0000-0003-2713-0836
Nejo, Takahide https://orcid.org/0000-0002-9191-8823
Colton Cove, Maggie https://orcid.org/0000-0002-7635-3748
Chen, Lee H.
Jung, Jangham
Okada, Kaori
Lakshmanachetty, Senthilnath
Gallus, Marco
Barpanda, Abhilash
Hong, Chibo
Chan, Gary K. L.
Liu, Jerry
Wu, Samuel H.
Ramos, Emilio
Yamamichi, Akane
Watchmaker, Payal B.
Ogino, Hirokazu https://orcid.org/0000-0002-2446-8789
Saijo, Atsuro https://orcid.org/0000-0002-7710-5498
Du, Aidan
Grishanina, Nadia R.
Woo, James
Diaz, Aaron https://orcid.org/0000-0001-9059-9501
Hervey-Jumper, Shawn L.
Chang, Susan M.
Phillips, Joanna J. https://orcid.org/0000-0002-3789-8120
Wiita, Arun P. https://orcid.org/0000-0002-7465-6964
Klebanoff, Christopher A. https://orcid.org/0000-0001-9645-3896
Costello, Joseph F. https://orcid.org/0000-0003-3189-584X
Okada, Hideho https://orcid.org/0000-0003-0076-9920
- License Information
-
More Information
Article History
Received: 26 October 2023
Accepted: 19 December 2024
First Online: 19 February 2025
Change Date: 6 March 2025
Change Type: Update
Change Details: In the version of the article initially published, the vertical order of the <i>y</i>-axis labels was reversed in Fig. 1d and has now been amended to read “STAD...COAD” from top to bottom in the HTML and PDF versions of the figure.
Competing interests
: C.A.K. and I.E. are inventors on patents related to public neoantigen-specific TCRs unrelated to the present manuscript and are recipients of licensing revenue shared according to Memorial Sloan Kettering Cancer Center institutional policies. C.A.K. has consulted for or is on the scientific advisory boards for Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Bristol Myers Squibb, Catamaran Bio, Cell Design Labs, Decheng Capital, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics, PACT Pharma, Roche/Genentech, Royalty Pharma and T-knife. C.A.K. is a scientific co-founder and equity holder in Affini-T Therapeutics.
